Survival-Adjusted FEV1 and BMI Percentiles for Patients with Cystic Fibrosis before the Era of Triple CFTR Modulator Therapy in Germany

被引:4
|
作者
Dittrich, A. Susanne [1 ,2 ]
Dumke, Markus [3 ]
Kapl, Ferdinand [3 ]
Schneider, Philipp [2 ]
Wege, Sabine [1 ,2 ]
Graeber, Simon [4 ,5 ,6 ,7 ,8 ]
Stahl, Mirjam [4 ,5 ,6 ,7 ,8 ]
Herth, Felix J. [1 ,2 ]
Naehrlich, Lutz [9 ,10 ]
Mall, Marcus A. [4 ,5 ,6 ,7 ,8 ]
Sommburg, Olaf [2 ,11 ,12 ]
机构
[1] Univ Hosp Heidelberg, Dept Pneumol & Crit Care Med, Thoraxklin, Heidelberg, Germany
[2] German Ctr Lung Res DZL, Translat Lung Res Ctr Heidelberg TLRC, Heidelberg, Germany
[3] Stat Up, Munich, Germany
[4] Charite Univ Med Berlin, Dept Pediat Resp Med Immunol & Crit Care Med, Berlin, Germany
[5] Free Univ Berlin, Berlin, Germany
[6] Humboldt Univ, Berlin, Germany
[7] Charite Univ Med Berlin, Berlin Inst Hlth, Berlin, Germany
[8] German Ctr Lung Res DZL, Berlin, Germany
[9] Justus Liebig Univ, Dept Pediat, Giessen, Germany
[10] Mukoviszidose Inst gGmbH MI, Bonn, Germany
[11] Univ Hosp Heidelberg, Div Pediat Pulmonol & Allergy, Heidelberg, Germany
[12] Univ Hosp Heidelberg, Cyst Fibrosis Ctr, Ctr Pediat & Adolescent Med, Heidelberg, Germany
关键词
Cystic fibrosis; FEV1; BMI; Percentile; Mortality attrition; Survival; Disease severity; LUNG-FUNCTION; TEZACAFTOR-IVACAFTOR; PULMONARY-FUNCTION; DISEASE; SPIROMETRY; CHILDREN; AGE;
D O I
10.1159/000529524
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Pulmonary disease is the major cause for morbidity and mortality in cystic fibrosis (CF). In CF, forced expiratory volume in 1 s (FEV1) referenced against a healthy population (FEV1%predicted) and body mass index (BMI) do not allow for the comparison of disease severity across age and gender. Objectives: We aimed to determine updated FEV1 and BMI percentiles for patients with CF and to study their dependence on mortality attrition. Methods: Age- and height-adjusted FEV1 and BMI percentiles for CF patients aged 6-50 years were calculated from 4,947 patients of the German CF Registry for the period 2016-2019 utilizing quantile regression and a Generalized Additive Model for Location, Scale and Shape (GAMLSS). Further, survival-adjusted percentiles were estimated. Results: In patients with CF, FEV1 increased throughout childhood until maximal median values at 16 years in females (2.46 L) and 18 years in males (3.27 L). During adulthood, FEV1 decreased substantially. At 17 years of age, the 25th BMI percentile of patients with CF (females 18.50 and males 18.15 kg/m(2)) was below the 10th BMI percentile of the German reference cohort. From the age of 20 years, survival (96.3%) decreased tremendously. At 50 years of age (survival 15.0%), the 50th CF-specific FEV1 or BMI percentile among the survivors corresponded to the 92.5th percentile among the total CF birth cohort. Conclusions: Continuously updated disease-specific FEV1 and BMI percentiles with correction for survival may serve as age-independent measure of disease severity in CF (accessible via https://cfpercentiles.statup.solutions) .
引用
收藏
页码:351 / 360
页数:10
相关论文
共 8 条
  • [1] Reference percentiles for FEV1 and BMI in European children and adults with cystic fibrosis
    Boelle, Pierre-Yves
    Viviani, Laura
    Busson, Pierre-Francois
    Olesen, Hanne V.
    Ravilly, Sophie
    Stern, Martin
    Assael, Baroukh M.
    Barreto, Celeste
    Drevinek, Pavel
    Thomas, Muriel
    Krivec, Uros
    Mei-Zahav, Meir
    Vibert, Jean-Francois
    Clement, Annick
    Mehta, Anil
    Corvol, Harriet
    ORPHANET JOURNAL OF RARE DISEASES, 2012, 7
  • [2] Reference percentiles for FEV1 and BMI in European children and adults with cystic fibrosis
    Pierre-Yves Boëlle
    Laura Viviani
    Pierre-Francois Busson
    Hanne V Olesen
    Sophie Ravilly
    Martin Stern
    Baroukh M Assael
    Celeste Barreto
    Pavel Drevinek
    Muriel Thomas
    Uros Krivec
    Meir Mei-Zahav
    Jean-François Vibert
    Annick Clement
    Anil Mehta
    Harriet Corvol
    Orphanet Journal of Rare Diseases, 7
  • [3] Effect of Triple Combination CFTR Modulator Therapy on Sleep in Adult Patients with Cystic Fibrosis
    Welsner, Matthias
    Schulte, Tim
    Dietz-Terjung, Sarah
    Weinreich, Gerhard
    Stehling, Florian
    Taube, Christian
    Strassburg, Svenja
    Schoebel, Christoph
    Sutharsan, Sivagurunathan
    RESPIRATION, 2022, 101 (08) : 766 - 774
  • [4] Heterogeneity in Survival in Adult Patients With Cystic Fibrosis With FEV1 < 30% of Predicted in the United States
    Ramos, Kathleen J.
    Quon, Bradley S.
    Heltshe, Sonya L.
    Mayer-Hamblett, Nicole
    Lease, Erika D.
    Aitken, Moira L.
    Weiss, Noel S.
    Goss, Christopher H.
    CHEST, 2017, 151 (06) : 1320 - 1328
  • [5] Triple CFTR modulator therapy is associated with improved endocrine pancreatic function in patients with cystic fibrosis
    Steinack, C.
    Gaisl, T.
    Beuschlein, F.
    Matthew, S. Mace
    Ernst, M.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [6] Triple combination CFTR modulator therapy reduces the need for endoscopic sinus surgery in adult patients with cystic fibrosis
    Tagliati, Corrado
    Lanni, Giuseppe
    Battista, Davide
    Pantano, Stefano
    Ripani, Pietro
    CLINICAL OTOLARYNGOLOGY, 2024, 49 (02) : 243 - 246
  • [7] Changes in fecal elastase-1 following initiation of CFTR modulator therapy in pediatric patients with cystic fibrosis
    Stephenson, Kimberly G.
    Lingle, Abby J.
    Baumberger, Kelly A.
    Dellon, Elisabeth P.
    Esther Jr, Charles R.
    Meier, Ellen M.
    Oermann, Christopher M.
    Shenoy, Vivek K.
    Smith, Natalie R.
    Wimmer, Nicole S.
    Duehlmeyer, Stephanie R.
    Kam, Charissa W.
    Mckinzie, Cameron J.
    Poisson, Margaret O.
    Elson, E. Claire
    JOURNAL OF CYSTIC FIBROSIS, 2023, 22 (06) : 996 - 1001
  • [8] Lung Function in Patients with Cystic Fibrosis before and during CFTR-Modulator Therapy Using 3D Ultrashort Echo Time MRI
    Heidenreich, Julius Frederik
    Kuhl, Philipp Josef
    Grunz, Jan-Peter
    Hendel, Robin
    Metz, Corona
    Weng, Andreas Max
    Benkert, Thomas
    Hebestreit, Helge
    Bley, Thorsten Alexander
    Kostler, Herbert
    Veldhoen, Simon
    RADIOLOGY, 2023, 308 (01)